Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Harmony Biosciences has raised $248.0M in total funding. The most recent round was Post-IPO Secondary. The last funding was announced in October 2024.
Harmony Biosciences's investors include Valor Equity Partners, Vivo Capital, Blackstone Life Sciences, Novo Holdings, OrbiMed.
Harmony Biosciences is headquartered in Plymouth Meeting, United States.
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Harmony Biosciences is at the Post-IPO Secondary stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Harmony Biosciences — Funding & Investors." VCBacked, October 30, 2024, https://www.vcbacked.co/company/harmony-biosciences. Accessed July 27, 2026.
VCBacked. (2024). Harmony Biosciences — Funding & Investors. Retrieved July 27, 2026, from https://www.vcbacked.co/company/harmony-biosciences
{{cite web |title=Harmony Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/harmony-biosciences |website=VCBacked |access-date=July 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated